Stifel starts Lexeo at buy, cites ataxia and Alzheimer’s drug candidates (LXEO)
ismagilov Stifel has started coverage of newly public Lexeo Therapeutics (NASDAQ:LXEO) with a buy rating, saying it was bullish on the company’s lead drug candidate LX2006 in the treatment of Friedreich’s ataxia and sees a potential…